BPI
VYGR icon

BFC Planning, Inc.’s Voyager Therapeutics VYGR Stock Holding History

BFC Planning, Inc.’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14K Hold
4,000
– – ﹤0.01% 2192
2026
Q1 		$15.4K Hold
4,000
– – ﹤0.01% 1832
2025
Q4 		$15.7K Hold
4,000
– – ﹤0.01% 1853
2025
Q3 		$18.7K Buy
+4,000
New +$14.5K ﹤0.01% 1610

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

BFC Planning, Inc.'s VYGR Position: Q2 2026 in Review

BFC Planning, Inc. held its Voyager Therapeutics (VYGR) position steady in Q2 2026 at 4,000 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #2192.

BFC Planning, Inc. first reported a position in VYGR in Q3 2025 and has held it in 4 quarters since. The position peaked at $18.7K in Q3 2025. 137 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • BFC Planning, Inc. held 4,000 shares of Voyager Therapeutics worth $14K as of Q2 2026.
  • BFC Planning, Inc. left its Voyager Therapeutics share count unchanged in Q2 2026.
  • Voyager Therapeutics made up ﹤0.01% of BFC Planning, Inc.'s portfolio in Q2 2026, its #2192 holding.
  • BFC Planning, Inc. first reported a position in Voyager Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • BFC Planning, Inc.'s Voyager Therapeutics position peaked at $18.7K in Q3 2025.
  • 137 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on BFC Planning, Inc.'s 13F filing for Q2 2026, filed 29 Oct 2026.